Aminoglycoside-mediated promotion of translation readthrough occurs through a non-stochastic mechanism that competes with translation termination by Chowdhury, H.M. et al.
 The University of Bradford Institutional 
Repository 
http://bradscholars.brad.ac.uk 
This work is made available online in accordance with publisher policies. Please refer to the 
repository record for this item and our Policy Document available from the repository home 
page for further information. 
To see the final version of this work please visit the publisher’s website. Access to the 
published online version may require a subscription. 
Link to publisher’s version: https://doi.org/10.1093/hmg/ddx409 
Citation: Chowdhury HM, Siddiqui MA, Kanneganti S et al (2018) Aminoglycoside-mediated 
promotion of translation readthrough occurs through a non-stochastic mechanism that competes 
with translation termination. Human Molecular Genetics. 27(2): 373-384. 
Copyright statement: © The Author 2017. Published by Oxford University Press. All rights 
reserved. For Permissions, please email: journals.permissions@oup.com 
Reproduced in accordance with the publisher's self-archiving policy. 
This is a pre-copy-editing, author-produced PDF of an article accepted for publication in Human 
Molecular Genetics following peer review. The definitive publisher-authenticated version 
Chowdhury HM, Siddiqui MA, Kanneganti S et al (2018) Aminoglycoside-mediated promotion of 
translation readthrough occurs through a non-stochastic mechanism that competes with 
translation termination. Human Molecular Genetics. 27(2): 373-384, is available online at: 
https://doi.org/10.1093/hmg/ddx409. 
 
1 
 
 
Aminoglycoside-mediated promotion of translation readthrough occurs through a 
non-stochastic mechanism that competes with translation termination 
H.M. Chowdhury 
1
, M. A. Siddiqui 
1
, S. Kanneganti 
1
, N. Sharmin 
2
 , M. W. Chowdhury 
2 
and Md. Talat Nasim 
1, 2, 3,4
*
 
 
1
 Department of Medical and Molecular Genetics, King’s College London, London, 
United Kingdom, 
2
School of Pharmacy and Medical Sciences, University of Bradford, 
Bradford, United Kingdom, 
3
National Institute for Health Research (NIHR), Biomedical 
Research Centre, Guy’s and St. Thomas’ NHS Foundation Trust and King’s College 
London, London, United Kingdom, 
4
Centre for Health Agricultural and Socio-economic 
Advancements (CHASA), Lalmonirhat, Bangladesh. 
 
Correspondence can be addressed to 
*Dr. M. T. Nasim 
School of Pharmacy and Medical Sciences 
University of Bradford 
Bradford BD7 1DP 
United Kingdom  
Tel. 01274 23 6076 
Email. t.nasim@bradford.ac.uk
2 
 
 
ABSTRACT 
Attempts have been made to treat nonsense-associated genetic disorders by chemical 
agents and hence an improved mechanistic insight into the decoding of readthrough 
signals is essential for the identification and characterisation of factors for the treatment 
of these disorders. To identify either novel compounds or genes that modulate translation 
readthrough, we have employed dual reporter-based high-throughput screens that use 
enzymatic and fluorescence activities and screened bio-active NINDS compounds 
(n=1000) and siRNA (n=288) libraries. Whilst siRNAs targeting kinases such as 
CSNK1G3 and NME3 negatively regulate readthrough, neither the bio-active NINDS 
compounds nor PTC124 promote readthrough. Of note, PTC124 has previously been 
shown to promote readthrough. Furthermore, the impacts of G418 on the components of 
eukaryotic selenocysteine incorporation machinery have also been investigated. The 
selenocysteine machinery decodes the stop codon UGA specifying selenocysteine in 
natural selenoprotein genes. We have found that the eukaryotic SelC gene promotes the 
selenocysteine insertion sequence (SECIS)-mediated readthrough but inhibits the 
readthrough activity induced by G418. We have previously reported that SECIS-
mediated readthrough at UGA codons follows a non-processive mechanism. Here, we 
show that G418-mediated promotion of readthrough also occurs through a non-processive 
mechanism which competes with translation termination. Based on our observations, we 
suggest that proteins generated through a non-processive mechanism may be 
therapeutically beneficial for the resolution of nonsense-associated genetic disorders.  
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INTRODUCTION 
There are more than 2500 genetic disorders caused by introduction of pre-mature 
termination codons (PTCs) into the reading frame. Examples of nonsense-associated 
genetic disorders include pulmonary arterial hypertension (PAH), cystic fibrosis, 
Duchene muscular dystrophy, Usher and Hurler syndromes. Human genes cannot 
normally be translated with in-frame stop codons with the exception of selenoprotein 
genes, which contain stop signals within their coding sequences. Decoding of the in-
frame stop signal UGA occurs through a quaternary complex consisting of a specialised 
selenocysteine tRNA
Sec
 (SelC), specific elongation factors, a specific RNA secondary 
structure (SECIS), and GTP (1-3). This in association with ribosomes, decodes the UGA 
signal to selenocysteine (4,5). Both similarities and dissimilarities have been observed 
between SECIS- and aminoglycosides-mediated promotion of readthrough events. For 
example, the fourth bases located immediately after the in-frame termination codon affect 
the efficiency of readthrough. Pyrimidines (cytosine and uracil) as a fourth base promote 
both SECIS and aminoglycosides-mediated readthrough (1). Whilst aminoglycoside-
mediated decoding of stop signals requires near cognate tRNA-codon interactions (6), 
selenocysteine incorporation requires the very specific tRNA
sec
 (1-3). Although SECIS 
elements in the SELENOP(SelP) (7) gene can decode 10 in-frame stop codons to make 
selenoprotein P, it is not known whether the readthrough agents can decode multiple stop 
signals. Hence, an improved understanding of decoding of nonsense codons is essential 
for the identification and characterisation of small molecule agents for the treatment of 
PTC-associated genetic disorders. 
 
Attempts have been made to identify small molecule compounds that promote translation 
readthrough of PTC-bearing transcripts aiming to resolve nonsense-associated disorders. 
To date, two high-throughput screens have been employed for the identification of small 
molecule agents that promote translation readthrough in mammalian cells (8,9).  These 
screens are based on measuring the function of a single gene and hence are neither 
suitable for determining the efficiency of readthrough nor functional characterisation of 
readthrough-promoting chemicals. Firstly, they are prone to much intrinsic variability at 
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the levels of RNA stability and translation. Secondly, compounds such as PTC124 that 
modulate reporter activity may generate false positive results. While investigating the 
mode of action of PTC124, Auld et al. found that the compound is a potent luciferase 
inhibitor, which outcompetes with the assay reagent generating an increased luciferase 
read-out (8). To overcome these difficulties, PTT-ELISA has been developed (9). Major 
limitations of this technique are that (a) the method is single gene-based and (b) the 
activity is determined through a conjugation of multiple steps and hence is time 
consuming. We and others have developed dual readthrough reporters which by-pass the 
variables confounding the single reporter functions (1,10-13). No mammalian dual 
reporter-based high-throughput screening of trans-acting factors either for small molecule 
compounds or for short interfering RNAs (siRNAs) has been reported yet. Recently, a 
dual-fluorescence high-throughput screen has been reported but this system is limited to 
yeast cells (14). Hence, there is a need to develop dual reporter-based high-throughput 
screens in mammalian cells capable of bypassing the variables confounding single 
reporter functions. 
 
In this report, we have developed mammalian cell-based dual-reporter screens and 
screened chemical (n=1000) and siRNA (n=288) libraries. We have found that siRNAs 
targeting the casein kinase 1 gamma 3 (CSNK1G3) and nucleotide diphosphate kinase 3 
(NME3) genes may negatively regulate readthrough. Additionally, neither PTC124 nor 
the bio-active compounds collected by National Institute of Neurological Disease 
Syndrome (NINDS) promote translation readthrough. We have demonstrated that 
aminoglycosides promote both basal and SECIS-mediated translation readthrough. In 
contrast, the SelC gene inhibited G418-mediated readthrough whilst the SelD (Sephs2) 
gene elicited no discernible effects. Furthermore, we have found that G418 sulfate-
mediated promotion of readthrough occurs through a non-stochastic mechanism and both 
translation termination and readthrough events compete with each other. Taken together, 
we propose a non-processive mechanism of translation readthrough as a therapeutic 
strategy for nonsense-associated genetic disorders. 
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RESULTS 
Development of an enzyme-based dual reporter high-throughput screen for 
determining the efficiency of stop codon readthrough in mammalian cells 
To overcome the limitations associated with single reporter-based high-throughput 
screens (8,9), we took advantage of our previously established dual-reporter assay based 
on genes encoding luciferase and β-galactosidase (1) . This reporter contains a segment 
harbouring an in-frame stop signal found within the selenoprotein phospholipid 
hydroperoxide glutathione peroxidase (PHGPx) gene. In the event of translation 
termination, -gal protein is generated, whilst readthrough produces a -gal and 
luciferase fusion protein (Figure 1A). The ratio of the activities of these two proteins thus 
determines the efficiency of readthrough. We first validated the assay system using G418 
sulfate, an established agent known to promote translation readthrough. To rule out any 
construct specific effect, we used two reporter constructs with varying lengths of the 
PHGPx fragment. We found that G418 sulfate promoted readthrough of both constructs 
(Figure 1B). Next, the efficiency of readthrough was determined using a series of 
constructs harbouring an in-frame stop codon and compared efficiencies with a construct 
where the stop codon was changed to a cysteine codon (Figure 1C). We found the 
readthrough efficiency of a nonsense codon is in between 0.2-1% compared with a sense 
codon (Figure 1D and Supplementary Figures 1A-B). The validity of the sense codon 
containing protein was carried out by western blot analyses using anti-luciferase antibody 
which detected the 178 KDa luc-gal fusion protein (Supp Figure 1C). 
 
We next investigated the effects of the so-called ‘fourth base’ located immediately after 
the UGA stop signal on readthrough efficiency. Constructs were generated with various 
fourth bases (Figure 1C) and their efficiencies were determined. Consistent with previous 
observations (15,16), we found that cytosine at the fourth base position promotes 
readthrough (Figure 1D and Supp Figure 1D) and G418-mediated readthrough is higher 
when pyrimidine instead of purine is the fourth base (Figure 1E). Western blot analyses 
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revealed higher level of luc-gal fusion protein in both UGAC and UGAU constructs 
following G418 treatment (Figure 1F).  
 
For further validation, UGAG (Supp Figure 2A), UGAU (Supp Figure 2B) and UGAC 
(Supp Figure 2C) constructs were taken forward and cells overexpressing these 
constructs were treated with varying concentrations of G418 to determine their 
concentration dependent effects.  G418 treatment promotes readthrough activities of all 
constructs in a concentration-dependent manner. Next, the effect of G418 was tested in a 
construct where the stop codon (UGAG) was changed to a cysteine codon (UGCG) (Supp 
Figure 2D). G418 treatment elicited no discernible effect on the UGCG construct. These 
data suggest the validity of readthrough and control constructs.  
 
Having validated the readthrough assay, we investigated the effect of other 
aminoglycosides including gentamicin and tobramycin on readthrough efficiency. Cells 
treated with these aminoglycosides promoted readthrough efficiency of constructs where 
the fourth base was either purine (Supp Figure 2E) or pyrimidine (Supp Figure 2F). 
However, we noticed that tobramycin-mediated promotion of readthrough was at a lower 
level compared with that induced by either gentamicin or G418 sulfate. 
 
The luc-gal based assay was further employed to investigate a number of nonsense alleles 
associated with cystic fibrosis, Duchene muscular dystrophy, Usher and Hurler 
syndrome. The nonsense codons (UGA or UAG) of the cystic fibrosis transmembrane 
conductance regulator (CFTR; p.G542X), alpha-L iduronidase (IDUA; p.Q70X), 
procadherin 15 (PCDH15; p.R245X) and dystrophin (DMD; p.R3381X) genes were 
introduced into the reading frames of lacZ and luciferase genes (Supp Figure 3A). 
HEK293T cells transiently transfected with these reporter constructs and treated with 
G418 sulfate showed an increase in the luc-gal ratio (Supp Figure 3B-F). Taken together, 
these data indicate the validity and usefulness of the luc-gal-based reporter assay for 
investigating the underlying mechanisms of readthrough for high-throughput screening of 
trans-acting factors.  
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Determination of readthrough activities of FDA-approved 1000 drugs  
To re-purpose FDA approved drugs for the resolution of nonsense-associated disorders, 
we screened 1000 bioactive NINDS compounds (Supp Table 1) at 10 µM using the 
UGAU construct (Supp Figure 4). The rationale for selecting this construct is that the 
readthrough efficiency is higher when pyrimidine as the fourth base. We first determined 
the Z-factor value of this assay. The Z-factor value indicates the suitability of the assay 
for high-throughput screening (17). The Z-factor value of this assay was 0.51, which 
indicates that this is a good high-throughput assay. 39 compounds showing two-fold 
higher activity over the basal readthrough were taken forward and their efficiencies were 
determined in a 3-point concentration response curve (Supp Table 2). None of the hits 
promoted readthrough activity in a concentration-dependent manner, with the exception 
of peruvoside, which promoted the luc-gal ratio at the concentration of 10µM. 
Readthrough promoting activity of this compound was further validated using a different 
fourth base construct (UGAG) and a control construct with a sense codon (UGCG). The 
compound failed to promote readthrough activity of the UGAG construct while it 
inhibited luciferase and β-gal activities of the control UGCG construct (Supp Figure 5A).  
Further inspection revealed that the compound inhibited the β-galactosidase activities of 
UGAG, UGAC and the control UGCG constructs and luciferase activity of the control 
UGCG construct. Thus anti-luc-gal activities of the compound might have contributed to 
the increased luc-gal ratio (Supp Figure 5B-E). Additionally, whilst we found that 19 
compounds inhibited readthrough activity at 0.1µM, ofloxacin and foscarnet sodium 
significantly inhibited readthrough at all concentrations used (0.1, 1 and 10µM) (Supp 
Table 2).  Taken together, these data suggest that whilst the FDA approved NINDS drugs 
do not promote translation readthrough, some compounds within this collection may 
interfere with translation termination. 
 
Identification of kinases that promote translation readthrough  
We next wished to identify novel kinases capable of modulating translation readthrough 
by screening a siRNA library (On Target Plus, Dharmacon) which targets 288 kinases. 
The kinases were randomly selected and the library was screened in 384-well format in 
triplicate using the UGAU construct at a standard concentration of 30nM (Supp Figure 
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6A). The wells deviating three standard deviations were considered as hits (n=10) which 
were further validated using the siGENOME SMARTpool siRNAs (Dharmacon). The 
siGENOME SMARTpool is a mixture of 4 siRNAs, all designed to target different 
regions of the single gene of interest.  siRNAs targeting the casein kinase 1 gamma 3 
(CSNK1G3) and nucleotide diphosphate kinase 3 (NME3) genes significantly inhibited 
readthrough activity. In contrast, siRNAs targeting the other 8 genes and non-targeting 
control (NTC) siRNAs showed no discernible effects (Supp Figure 6B).  
 
Development and validation of a dual-fluorescence readthrough reporter assay 
Having established the enzyme-based screen, we next developed a dual-fluorescence-
based readthrough assay aiming to investigate readthrough activity in single cells. The 
dual-fluorescence readthrough reporter is based on genes encoding DsRed-Express and 
EGFP. This assay was based on the same principle as used in the enzyme-based reporter 
with the exception that it harbours the BMPR2 gene bearing a pathogenic nonsense 
mutation identified in a subject with pulmonary arterial hypertension (PAH). The reporter 
was developed such that, in the event of readthrough, a dual-fluorescent protein 
consisting of DsRed Express and EGFP is produced, whilst translation termination 
generates only the DsRed-Express protein. Thus, the ratio of the fluorescence intensities 
of these two proteins determines the efficiency of readthrough (Figure 2A).  
 
The pTN139-PTC construct harbouring a nonsense codon expressed only the DsRed-
Express protein, which following the treatment of G418 sulfate, generated both EGFP 
and DsRed-Express proteins (Figure 2B). Of note, we earlier confirmed by means of 
fluorescence microscopy (18), RT-PCR and western blot analyses that this nonsense 
mutation introduces a PTC (Supp Fig 7A-B). To determine the efficiency of readthrough 
at the level of single cells, HEK293T cells expressing fluorescence reporters were sorted 
using a fluorescence-activated cell sorter (FACS). Mock transfected cells produced little 
or no background fluorescence (Figure 2Ci) whilst cells containing the pTN139 construct 
generated the highest level of dual-fluorescence (Figure 2Civ). In contrast, cells bearing 
the 139-PTC construct generated little dual-fluorescence (Figure 2Cv).  A significantly 
high proportion of the cells generated dual-fluorescence following gentamicin treatment 
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which validates the assay system (Figure 2Cvi and 2D). By determining the fluorescence 
intensity ratios of DsRed-Express to EGFP using a fluorescence plate reader, which 
indicates the degree of readthrough, we further confirmed that the assay detects 
gentamicin-mediated translation readthrough (Figure 2E).  
 
We provided extensive evidence that there is a good correlation between the enzyme and 
fluorescence assays that fluorescence assay could be used as a secondary screen to verify 
the hits to reduce false positive and false negative results. Firstly, as the enzyme-based 
assay was based on the stop codon UGA, we mutated the UAG codon of the fluorescence 
reporter to UAA and UGA stop codons and determined their readthrough efficiencies in 
HEK293T cells. Consistent with existing literature, we found that the readthrough 
efficiency was higher when the internal stop signal was the UGA codon compared with 
that of either UAG or UAA codons (Supp Figure 7C) (19). Secondly, we tested a number 
of compounds including G418, gentamicin and peruvoside using the construct harbouring 
the UGA stop codon.  Consistent with the luminescence data, the fluorescence results 
showed that aminoglycosides including G418 sulfate and gentamicin promoted 
readthrough, whilst peruvoside elicited no discernible effect (Supp Figure 8A).     
 
PTC124 does not promote translation readthrough 
We next determined the impact of PTC124 on readthrough and provided extensive 
evidence that this compound does not promote readthrough. First, the readthrough 
potential of PTC124 was investigated using the luc-gal-based double reporter 
readthrough assays. Briefly, constructs containing the nonsense codons (UGA or UAG) 
of the CFTR(p.G542X), IDUA(p.Q70X), PCDH15(p.R245X), DMD(p.R3381X) and 
PHGPx(p.59X) genes (Supp Figure 3A) were transiently transfected into HEK293T cells 
and treated with either G418 sulfate or PTC124. Cells treated with G418 sulfate showed 
an increase in the luc-gal ratio. In contrast, cells treated with PTC124 at 0.1, 1.0 and 10 
μM, which elicit the most readthrough activity (20), failed to increase the luc-gal ratio 
(Figure 3A).  Second, the influence of the fourth base on PTC124-mediated readthrough 
was investigated using the readthrough constructs where the fourth base immediately 
after the internal stop signal of the PHGPx gene was changed to adenosine (A), cytosine 
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(C) or uracil (U) (Figure 1C). A pyrimidine base as the fourth base resulted in a higher 
G418-mediated readthrough than a purine (Figure 1E), whilst PTC124 failed to promote 
luc-gal ratio of these constructs (Figure 3B). However, we noticed that PTC124 showed a 
tendency to reduce luc-gal ratio and in fact, this inhibition was significant at 10µM for 
UGAC. Next, the identity of the readthrough protein was verified by western blot 
analysis. As expected, G418 increased the production of the readthrough protein in the 
CFTR nonsense (p.G542X) construct while PTC124 generated no detectable full-length 
protein (Figure 3C). Finally, we tested PTC124 using fluorescence constructs harbouring 
either UAG or UGA or UAA stop codons and found that the agent at 10µM failed to 
promote readthrough of any of these fluorescence constructs (Supp Figure 8B).  
 
Translation readthrough events compete with translation termination 
The effect of release factors including eRF1 and 3 was investigated using a pyrimidine as 
the fourth base construct (UGAU). Overexpression of either eRF1 or eRF3 significantly 
reduces readthrough activity (Figure 4A). We found that knocking down of eRF1 using 
siRNA increased the readthrough activity (Figure 4B) which is inversely correlated with 
the overexpression experiment. However, siRNAs targeting eRF3 failed to elicit any 
discernible effects. Next, we investigated if the components of the eukaryotic 
selenocysteine incorporation machinery including the SECIS element, the tRNA
sec
 (SelC) 
and SelD (Sephs2) promote readthrough activity. Consistent with previous observations, 
we found that incorporation of SECIS element at 3’UTR (Figure 4C) increased the 
activity of this UGA-SECIS construct up to 20 folds (Figure 4D), which was further 
increased when the cells were either treated with sodium selenite, an agent known to 
charge the tRNA
sec 
in the absence and presence of SelC (Figure 4E) or G418 sulfate 
(Figure 4F) (21-23). In contrast, overexpression of SelC inhibited G418-induced 
readthrough activities whilst SelD elicited no discernible effects (Figure 4G).  
 
G418-promoted readthrough is significantly reduced at multiple stop signals 
To develop an assay that can detect readthrough at multiple stop signals, we introduced 
three in-frame stop signals, one from the PHGPx and two from the selenoprotein P gene, 
into the enzyme-based reporter. Site-directed mutagenesis was carried out to create a 
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number of additional constructs that harbour various combinations of multiple in-frame 
stop signals (Figure 5A). The readthrough efficiency of these constructs was then 
determined in the absence and presence of G418 sulfate (400µg/ml). Both basal (Figure 
5B) and G418-mediated readthrough (Figure 5C) were higher for transcripts containing 
one stop signal than for those containing two or more stop signals. Western blot analysis 
showed the production of the full-length fusion protein following G418 treatment when 
constructs containing one stop signal were used. In contrast, full length protein 
production was markedly reduced when constructs with two or three stop signals were 
employed (Figure 5D).  
 
G418 sulfate inhibits excessive proliferation in primary mouse PASMCs  
Finally, we investigated whether readthrough compounds elicit beneficial effects in a 
disease-relevant ex vivo cell-based assay. Primary PASMCs derived from mutant mice 
harbouring a pathogenic nonsense mutation (p.R899X) showed excessive proliferation 
compared with cells derived from wild-type animals and TGFβ1 stimulation further 
increased proliferation of mutant cells (Figure 6A, 6C), which are consistent to our 
previous observations (24,25). Treatment of cells with G418 inhibited excessive mutant 
cell proliferation (Figure 6A), whilst PTC124 failed to show any discernible effects on 
both wild-type and mutant cells (Figure 6B-C). However, the compound only at 10µM 
slightly inhibited excessive mutant cell proliferation induced by TGFβ1 stimulation 
(Figure 6C).  
 
DISCUSSION 
We present mammalian cell-based double reporter readthrough screens and provide novel 
mechanistic insights into the translation readthrough process. Whilst this study identifies 
kinases such as CS3K1G and NME3 as potential regulators, the bio-active NINDS 
compounds and PTC124 do not promote readthrough. Compounds within the NINDS 
collection including ofloxacin and foscarnet sodium may modulate the translation 
termination process. The SelC gene, which encodes for the tRNA
 sec
 has opposing effects 
on readthrough. This tRNA promotes SECIS-mediated readthrough and inhibits the 
readthrough activity promoted by G418 sulfate. We have previously reported that SECIS-
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mediated readthrough occurs through a non-processive mechanism (1). Here, we show 
that G418-mediated readthrough does not follow a stochastic process, rather it also 
follows a non-processive mechanism.  
 
The limitations of currently used single reporter-based high-throughput screens (8,9) and 
the use of bi-cistronic reporters for investigating underlying mechanisms readthrough 
(1,10-13) prompted us to develop dual-reporter based screens. We have demonstrated a 
number of ways that our high-throughput screening assays bypass the limitations 
associated with single reporter functions. Firstly, our mammalian cell-based double-
reporter screens minimize the variables such as variation between samples at the levels of 
transcription, RNA stability and translation. Secondly, since our techniques are based on 
measuring the ratio of two reporter activities, they are suitable for determining the 
efficiency of cis or trans-acting factors that affect either the translation termination or 
readthrough process. For example, compounds including ofloxacin and foscarnet sodium 
significantly reduced the readthrough efficiency which suggests that these molecules are 
likely to affect the translation termination process. Thirdly, false positive compounds that 
interact either with assay substrates or affect the activity of a reporter can easily be 
identified. We have provided extensive evidence that PTC124 does not promote 
readthrough and peruvoside is a potent β-galactosidase and luciferase inhibitor. Finally, 
whilst the enzyme-based assay provides higher sensitivity, the advantages of 
fluorescence-based assay are that the activity is measured in single cells without cell lysis 
and substrate addition (14) and the fluorescence assay can provide an additional mean to 
verify the hits to reduce false positive and false negative results.  
 
However, these screens have several limitations.  For example, the fluorescence-based 
assay was found to be less sensitive than the enzyme-based assay. The fluorescence-
based assay is subject to interference from autofluorescence, which may interfere with 
eGFP fluorescence. This could be easily corrected by swapping eGFP for the DsRed-
Express reporter. The drawbacks associated with the enzyme-based assay are that factors 
affecting luciferase or β-galactosidase activities may generate false positive or false 
negative results. These false positive or negative results could easily be detected using 
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control constructs harbouring a sense codon instead of a stop signal (Supp Figure 5A, D-
E). However, these limitations are unlikely to affect the usefulness of these techniques as 
long as an independent method such as western blot analysis or RT-PCR is used to 
validate the positive hits identified through the initial screen. As our pilot screen detected 
established readthrough compounds, high-throughput screenings that employ a diverse 
set and a larger number of molecules are likely to identify novel readthrough agents.   
 
The strategy of screening a pilot library collection identified NME3 and CSNK1G3 
kinases as potential modulators of readthrough, suggesting that additional genes in this 
pathway would be likely to be identified from a genome-wide siRNA screen. NME3 
plays a major role in the synthesis of nucleoside triphosphate and CSNK1G3 
phosphorylates a large number of proteins such as caseins.  However, further studies are 
required to establish their roles in readthrough and whether they present druggable targets 
for the resolution of nonsense-associated genetic disorders. Re-purposing of NINDS 
drugs for PTC-associated disorders is a distant possibility as these drugs do not harbour 
any readthrough promoting activity. PTC124 has been shown to elicit beneficial effects 
in cystic fibrosis and Duchene muscular dystrophy model systems (26,27) but its inability 
to promote readthrough in cell-based assays and failure to restore cellular defects in the 
mouse PASMCs harbouring a nonsense mutation support the finding that this agent is not 
a general promoter of readthrough. Non-antibiotic compounds have been identified all the 
time and some of these chemicals have been tested in preclinical and clinical trials (9,28). 
Failure of PTC124 in this and other assays (8,29)  emphasize the need for further 
investigation of these readthrough agents including their mode of action and impact on 
processivity prior to testing them in animals and in clinical trials.   
 
It is essential to determine whether the readthrough-promoting chemicals follow a 
processive or non-stochastic mechanism as each of these mechanisms is likely to impact 
on the therapeutic efficacy of the readthrough agents. In the processive model, the agent 
decodes the PTC by re-programming the translating ribosomes. When a second stop 
signal enters the ribosomal A site, the re-programming ribosomes decode the stop signal 
with the same efficiency as the first stop codon (Figure 7A-B). Processivity is the likely 
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explanation for decoding of 10 in-frame stop signals found in the SELENOP gene (1). In 
contrast, in the non-stochastic model, the readthrough agent transiently associates with 
the translating ribosomes, decodes the stop signal with a sub-optimal efficiency and 
dissociates from the complex once decoding is completed (Figure 7C-D). When a second 
stop signal enters the ribosomal A sites, the decoding complex needs to be formed again. 
Efficiency of decoding of both stop signals will be the cumulative product of all 
incorporation efficiencies. G418-mediated promotion of readthrough is significantly 
reduced in the presence of two or three stop signals, which suggests that aminoglycoside-
mediated readthrough does not follow the processive mechanism rather the readthrough 
occurs through a non-stochastic process. We have previously reported that SECIS-
mediated readthrough also follows a non-processive mechanism (1). Taken together, it 
appears that proteins generated through a non-processive mechanism, may be 
therapeutically beneficial compared with those generated via the processive model for a 
number of reasons. Firstly, the probability for the generation of an extended protein that 
bypasses the bonafide stop signal in a PTC harbouring transcript is relatively low as the 
readthrough efficiency is directly proportional to the multiplicative product of all 
readthrough efficiencies. Secondly, the extended protein is likely to be decayed due to the 
presence of unstable peptides derived from the translation of 3’UTR (30). Finally, the 
processive mechanism is likely to generate proteins, which will harbour more mutated 
amino acid residues compared with the proteins generated through the non-stochastic 
process. 
 
Furthermore, we show that the efficiency of a stop codon readthrough is below 1% and  
that pyrimidine residues in the ‘fourth base’ position relative to the internal stop signal 
promote both basal and aminoglycoside-mediated readthrough, which all are in line with 
previous observations (15,31,32).  G418-mediated readthrough efficiency is higher in the 
presence of a pyrimidine, which may favour the recruitment of suppressor tRNAs to the 
stop signal (33,34). In contrast, in the presence of a purine, which favours the binding of 
release factors to the stop signal (35), G418-promoted readthrough was significantly 
reduced. In the presence of release factors eRF1 and eRF3, both basal and G418-induced 
readthrough events are significantly reduced suggesting a direct competition between 
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termination and readthrough events (36,37). Aminoglycosides have been suggested to 
promote translation readthrough and selenocysteine incorporation (21-23) by interfering 
with translation elongation (38,39). The inability of tRNA
sec
 to promote both basal and 
aminoglycoside mediated readthrough suggests its specificity for decoding stop signals.  
 
In conclusion, we report a number of useful screens and assays for determining the 
efficiency and investigating the underlying mechanisms of translation readthrough in 
mammalian cells. We have demonstrated that neither PTC124 nor the bio-active NINDS 
drugs promote readthrough. Compounds within the NINDS collection including 
ofloxacin and foscarnet sodium and kinases such as NME3 and CSNK1G3 may regulate 
the translation termination machinery. Furthermore, we have found that aminoglycosides-
mediated promotion of readthrough occurs through a non-processive mechanism that 
competes with translation termination. Molecules with improved suppression activity that 
follow the non-processive mechanism should expand the utility of inducers of 
readthrough to control translation-based gene regulation and may have important clinical 
applications for the treatment of PTC-associated genetic disorders. 
 
MATERIALS AND METHODS  
Compounds 
G418 sulfate and gentamicin were purchased from Promega and PTC124 was purchased 
from Selleckchem. G418 and gentamicin were dissolved in water whilst PTC124 was in 
DMSO. All chemicals were kept at -20
o
C until use. 
 
Plasmid construction 
Nucleotide sequences correspond to amino acids from 526 to 559 of human CFTR 
(MIM:602414), from 229 to 262 of PCDH15 (MIM:605514), from 3365 to 3398 of DMD 
(MIM:300377) and from 54 to 87 of IDUA (MIM:252800) genes harbouring the 
nonsense codons were cloned into SalI and BamHI sites of pBPLUGA (10) and the 
respective clones were verified by sequencing (DNA cloning Service, Germany).  The 
details of the other luc-gal-based reporter constructs were published earlier (1,10). 
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Single-cell based dual-fluorescence readthrough assay constructs were generated in 
several steps.  First, the pEGFP gene was cloned into the BamHI and XbaI sites of the 
DsRed-Express-C1plasmid (Clonetech), which resulted in the DsRed Express-EGFP 
vector. Next, the exon 9 of plasmid pTN136 (18) was replaced with exon 12 of BMPR2 
gene using PCR mutagenesis (40). The resultant splicing unit was cloned into XhoI and 
BamHI sites of the DsRed Express-EGFP vector and designated as pTN139. Finally, 
plasmid pTN139PTC was generated by substituting ‘T’ with ‘G’ at position 2620 of the 
exon 12 such that, it introduced a stop signal (TAG) (18). Site directed mutagenesis was 
initiated to change the TAG codon to TAA and TGA codons.  
 
Cell culture, transient transfection, treatment of cells with chemical agents, 
enzymatic and fluorescence assays and western blots  
Cell culture and transfections were carried out as described elsewhere (41), (42-44). The 
amount of plasmid DNA transfected into the HEK293 and HEK293T cell lines varied 
from assay to assay (from 30 ng to 1 g). 24 hours after transfection, cells were treated 
with compounds in DMEM containing 0.1% FBS for an additional 24 hours. Cell lysate 
was prepared as described earlier (24,25) and Luciferase and β-galactosidase activities 
were determined with the Dual-light Reporter Assay (Applied Biosystems) using an 
ORION-II Plate Luminometer (Berthold) according to the manufacturer’s protocols. For 
determination of fluorescence intensity, cells were grown in 96 well black plates and 24 
hours after transfection, cells were treated with compounds in DMEM containing 0.1% 
FBS, and grown for an additional 48 hours. At the time of measurement, the medium was 
discarded and the fluorescence intensities were determined using BMG Labtech Omega 
fluorescence plate reader. Fluorescence microscopy and fluorescence activated cell 
sorting (FACS) were carried out as described elsewhere (41-44). Western blots were 
carried out using anti-luciferase (Calbiochem) and anti-GFP (AbCam) antibodies 
following manufacturer’s protocols. To confirm equal loading, the membranes were 
stripped and re-probed with anti-β-actin antibody (Cell Signaling). 
 
RNA isolation, cDNA synthesis and reverse Transcriptase PCR (RT-PCR) 
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RNA was isolated from mammalian cells using either TRI-Reagent (Sigma) or RNeasy 
Purification kit (Qiagen). cDNA was synthesized using random primers and M-MLV 
Reverse Transcriptase (Promega) following the manufacturer’s protocol. The PCR was 
carried out using Hi-Fidelity Extensor Master Mix (ABgene).  
 
Screening of small molecule compounds  
Screening of the NINDS was carried out in HEK293T cells in 96-well plate format. 
10,000 cells were grown in half area 96 well clear plates and 24 hours after seeding cells 
in each well were transfected with 25ng of readthrough reporter plasmid using Gene 
Jammer Transfection Reagent (Stratagene) following manufacturer’s protocol. 24 hours 
after transfection, cells were treated with compounds (10µM) in DMEM containing 0.1% 
FBS, and grown for an additional 24 hours. Cell lysate was prepared using Reporter Lysis 
Buffer (Promega) and the lysate was transferred to white plates and luc-gal activities 
were measured as described above.   
 
siRNA screening and hit validation 
The siRNA screen in mammalian cells was carried out at the Sheffield siRNA Screening 
Facility, University of Sheffield. The luc-gal-based readthrough assay system containing 
pyrimidine as the fourth base (UGAC construct) was employed. A total of 288 siRNAs 
were screened in 384-well format in triplicate in HEK293T cells. Briefly, HEK293T cells 
were transfected with UGAC plasmid in T75 flasks and 24 hours following transfection, 
the cells were reverse transfected with siRNAs in 384-well format using Dharmafect1 
(Dharmacon). Three days following siRNA transfection (30nM), the cells were harvested 
and their luc-gal activities were determined using a Varioskan SK plate reader (Thermo). 
For the primary screen, On Target Plus siRNA library (Dharmacon) was used, containing 
a pool of four individual siRNAs per gene. The wells deviating 3 standard deviations 
(3SD) were considered as hits and the hits were validated using siGENOME SMART 
pool siRNAs (Dharmacon) at a concentration of 30nM in 96-well format. siGENOME 
SMART pool siRNAs (Dharmacon) at a concentration of 30nM were used to knock 
down eRF1 and eRF3 genes. 
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Quantitation of proliferation of mouse primary PASMCs 
Quantitation of cell proliferation was carried out as described elsewhere (24,25). Briefly, 
mouse PASMCs were grown in 96-well plates. Cells were treated with either G418 
sulfate or PTC124 in DMEM containing 0.1% FBS and grown for an additional three 
days. Relative rate of proliferation was carried out using CellTiter 96
®
 Aqueous One 
Solution Cell Proliferation Assay (Promega) following manufacturer’s instruction. 
 
Statistics 
Statistical analysis was performed following paired Student’s t-test.  The Z-factor was 
calculated following a protocol described elsewhere (17). Comparison of multiple means 
was carried out using ANOVA followed by Tukey’s post hoc test.   
 
 
 
FIGURE LEGENDS  
Figure 1 
(A) An outline of the enzyme activity reporter. In brief, translation termination in the 
internal stop signal generates the -gal protein. In the event of readthrough, a -gal-
luciferase fusion protein will be produced. Thus, the ratio of the two reporter activities 
indicates the efficiency of readthrough. Two independent constructs, H8 (pBPLUGA; 
(10)) and H8A (1), were used in this study to rule out any construct specific effect. 
Construct H8 contains a 17 bp fragment of the PHGPx gene harbouring an in-frame stop 
signal whilst H8A contains a 91 bp DNA fragment. The luc-gal ratio was markedly 
increased in both constructs following G418 sulfate (400µg/ml) treatment (B). An outline 
of the constructs to determine the effect of ‘fourth bases’ on stop readthrough (C). The 
stop codon UGA was changed to a cysteine (UGU) codon and the fourth base ‘G’ was 
changed to either ‘A’ or ‘C’ or ‘U’ as indicated by arrows.  The efficiency of stop codon 
readthrough (D) and the effect of the ‘fourth base’ on both basal and G418 sulfate-
mediated (E) translation readthrough. Western blot analysis of proteins generated from 
pyrimidine harbouring constructs (UGAC and UGAU) in the absence and presence of 
G418 treatment (F).**P<0.01 and ***P<0.001 compared with untreated control. 
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Figure 2 
Determination of readthrough in single cells. An outline of the fluorescence-based 
translation readthrough assay (A). The principle of the reporter system is similar to that 
mentioned in Figure 1 with the exception that it contains a translation termination signal 
in exon 12 of the BMPR2 gene and that luciferase and -galactosidase genes are replaced 
by genes encoding EGFP and DsRed-Express proteins. Exon 12 of BMPR2 is fused in-
frame to an adenovirus splicing unit (41) so that it generates a DsRed-EGFP fusion 
protein. Introduction of a premature termination codon (PTC) into exon 12 leads to the 
production of the DsRed-Express protein only. Live cell imaging of G418 sulfate 
untreated (upper panel) and treated (400µg/ml) (lower panel) HEK293T cells transfected 
with the PTC containing construct (139PTC) (B). Determination of readthrough by FACS 
analysis (C). Cells transfected with pTN139 generated the highest proportion of dual-
fluorescence cells (Civ), whilst 139PTC produced few dual-fluorescence cells (Cv). The 
population of 139PTC-derived dual-fluorescence cells was markedly increased following 
gentamicin (Cvi and E) treatment (600µg/ml). EGFP- (Cii) and DsRed-Express– (Ciii) 
expressing cells were used as fluorescence positive controls, whilst mock transfected 
cells (Ci) were used as a negative control. Cells expressing the 139-PTC construct treated 
with gentamicin showed increased the ratio of eGFP-DsRed fluorescence intensities (D) 
and the number of dual-fluorescence cells (E) as determined by a fluorescence plate 
reader and FACS analysis, respectively. Values derived from untreated cells were set as 
100. **P<0.01 compared with untreated control. 
 
Figure 3 
PTC124 fails to promote translation readthrough. HEK293T cells transiently transfected 
with human CFTR (p.G542X), PCDH15 (p.R245X), DMD (p.R3381X), IDUA (p.Q70X), 
or pig PHGPx (p.59X) were treated with G418 (400µg/ml) or increasing concentrations 
of PTC124 (A). Cells were transfected with various PHGPx constructs (p.59X) 
containing adenosine (A), cytosine (C), guanine (G) or thiamine (T) in the fourth base 
position (underlined) and were treated with G418 (400µg/ml) (B) or increasing 
concentrations of PTC124 (B). Western blot analysis of HEK293T cells transiently 
20 
 
transfected with the CFTR (p.G542X) dual reporters following treatment with G418 or 
increasing concentrations of PTC124 for luciferase and β-actin proteins (C). The dual 
reporter generated a fusion protein of approximately 178 KDa. G418 not PTC124 
increased the expression of this protein in cells transfected with CFTR nonsense 
(p.G542X) construct. ***  P< 0.001, NS- non-significant compared with untreated cells. 
 
Figure 4 
Competition between translation readthrough and termination events. Effects of eRF1 
and 3 on readthough by means of plasmid overexpression (A) and siRNA knock down 
(B) determined by enzyme-based assay using the UGAU construct. An outline of SECIS-
mediated readthrough construct where the SECIS element was introduced in the 3’UTR 
(C). Readthrough efficiency of the UGAG-SECIS construct compared with the construct 
without the SECIS element (D). Effects of SelC and Na2SO3 (2µM) (E) and G418 
(400µg/ml) (F) on SECIS-mediated readthrough. Effects of SelC and SelD on both basal 
and G418-mediated readthrough assessed on the UGAU construct (G).  ** P< 0.01, ***p 
< 0.001 compared with untreated cells. NS- non-significant. 
 
Figure 5 
Translation readthrough at successive PTCs. (A) A segment of the SELENOP gene 
(accession number z11793; from nucleotides 934–990) containing two UGA codons was 
inserted into the enzyme-based reporter (Figure 1A). The diagram indicates the relative 
positions of the PHGPx and SELENOP UGA codons. PTC and sense codon are indicated 
by ‘I’ and ‘O’, respectively. Translation readthrough at multiple sites in the absence (B) 
and presence of G418 treatment (C). (D) Western blot analysis of readthrough protein 
detected by anti-luciferase antibody. G418-mediated readthrough resulted in the 
production of the gal-luc fusion protein in the presence of one PTC but not two or three 
PTCs (Upper panel). The blot was stripped and reprobed with β-actin antibody (lower 
panel) to demonstrate equal loading. The control cells were mock transfected.  **P<0.01 
and ***P<0.001 compared with IOO construct (B). ***P<0.001 compared with 
constructs containing one stop signal (C). 
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Figure 6 
Resolution of nonsense-associated cellular defects using readthrough compounds. (A) 
Inhibition of excessive cell proliferation by aminoglycosides. The relative rate of 
proliferation in wild-type (WT bmpr2 
+/+
) and mutant (bmpr2 
R899X+/-
) mouse primary 
PASMCs. Effects of G418 sulfate on proliferation of both wild-type and mutant 
PASMCs. ***P<0.001 compared with untreated control. Effects of PTC124 on wild type 
(B) and mutant PASMCs following TGFβ1 stimulation (C). Concentrations of the 
compound and the ligand are indicated below graphs. *P<0.05 compared with cells 
stimulated with TGFβ1.  
 
Figure 7 
Processive and non-processive models of translation readthrough. A diagram depicting 
normal translation termination showing dissociation of translating ribosomes (A).  
Processive model of readthrough in transcripts harbouring a PTC (B).  Translating 
ribosomes associate with transcripts whereby the 3’UTR together with readthrough 
complex determines the efficiency of decoding of all successive in-frame stop signals. 
Processivity is the likely explanation for the synthesis of selenoprotein P, which contains 
10 in-frame stop signals. Non-processive mechanism of readthough in transcripts with a 
PTC where ribosomes dissociate both at PTC and stop signals in the absence (C) and 
presence (D) of a readthrough agent. In non-processive model, production of readthrough 
proteins are directly proportional to multiplicative sum of all incorporation efficiencies 
and polypeptides that bypass stop signal are likely to be degraded due to the presence of 
destabilizing peptides at the C-terminal end (30). Downward and rightwards arrows 
indicate the efficiency of translation termination and readthrough, respectively. RA-
readthrough agents, UTR- untranslated region, 
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